Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs (EDEN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01532882
Recruitment Status : Completed
First Posted : February 15, 2012
Last Update Posted : April 29, 2013
Information provided by (Responsible Party):
Laboratoire Innotech International

Brief Summary:

Diosmin has a well established use status in improvement of the symptoms of venolymphatic insufficiency: heavy legs, pain, primo-decubitus restlessness and as complement treatment of capillary fragility.

Nevertheless, diosmin 600 mg did not benefit from a rigorous clinical study versus placebo, to establish its efficacy in the pain relief in Chronic Venous Disease (CVD).

The aim of this project led by Dr. Guex is to evaluate the efficacy and safety of diosmin 600 mg - DIOVENOR® on the painful symptoms of CVD of the lower limbs, in a multicentre, controlled, randomised, double blind, placebo-controlled, parallel-group study.

Condition or disease Intervention/treatment Phase
Chronic Venous Disease of Lower Limbs Drug: Diosmin Drug: Placebo Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 378 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups
Study Start Date : January 2012
Actual Primary Completion Date : March 2013
Actual Study Completion Date : April 2013

Arm Intervention/treatment
Experimental: Diosmin Drug: Diosmin
tablet, 600mg, PO, 1 tab per day during 28 days

Placebo Comparator: Placebo Drug: Placebo
tablet, PO, 1 per day during 28 days

Primary Outcome Measures :
  1. Change of Visual analog Scale score for assessment of the painful venous symptomatology [ Time Frame: baseline and after 28 days ]

Secondary Outcome Measures :
  1. - Painful symptom intensity (daily VAS score) Area Under the Curve [ Time Frame: 28 days ]
  2. - Daily VAS score for Response rate [ Time Frame: 28 days ]
  3. - Daily VAS score for Time to response [ Time Frame: 28 days ]
  4. - Score of Quality of life questionnaire (SQOR-V) [ Time Frame: Between baseline and 28 days ]
  5. - Patient's and physician's global satisfaction score [ Time Frame: At 28 days ]
  6. Adverse Events (numbers and frequency) [ Time Frame: 28 days ]
  7. - Unusual intakes of analgesic treatments (rate of patients) [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient, man or woman, aged 18 and over,
  2. Patient presenting a C1s or C2s venous disease grade of the lower limbs
  3. Patient presenting a painful venous symptomatology in the lower limbs for at least 15 days.
  4. Patient suffering from venous symptomatology in one leg with a painful symptom intensity higher or equal to 30 mm (VAS= 100mm)

Exclusion Criteria:

  1. Patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion,
  2. Patients who started treatments such as calcium inhibitors, beta-blockers, angiotensin converting enzyme inhibitors and/or vasodilators and/or vasoconstrictors within 28 days prior inclusion (for patients already taking this type of treatments, dosage should not have been changed in the 28 days prior inclusion and should not be planned to change in the course of the study),
  3. Patient treated by any analgesic within 7 days prior inclusion,
  4. Patient treated by an anti-inflammatory treatment within 7 days prior inclusion,
  5. Patient using elastic venous compression
  6. Patient presenting permanent oedema,
  7. Patients presenting venous skin changes,
  8. Patient whose activity in the 4 following weeks (that is to say during the study) would be different from his/her usual activities (before the study),
  9. Patient suffering from a pathology generating other pains than venous pains in the lower limbs,
  10. Patient with a history of lower limbs trauma responsible for sequel pains,
  11. Patient with a known deep venous reflux,
  12. Patient with a history of venous thromboses or thrombo-embolic diseases within the last 6 months before inclusion,
  13. Patient treated with analgesics or anti-inflammatory treatments used as analgesics within 4 weeks prior inclusion
  14. Patient having a known hypersensitivity to diosmin or one of the excipients
  15. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption ),

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01532882

Dr Jean-Jérôme GUEX
Nice, France, 06000
Sponsors and Collaborators
Laboratoire Innotech International
Principal Investigator: Jean-Jérôme GUEX, MD

Responsible Party: Laboratoire Innotech International Identifier: NCT01532882     History of Changes
Other Study ID Numbers: DIO401-10
First Posted: February 15, 2012    Key Record Dates
Last Update Posted: April 29, 2013
Last Verified: April 2013